{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:40:37Z","timestamp":1790775637317,"version":"4.1.0"},"reference-count":43,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Viatris","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100015756","name":"Janssen-Cilag","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"crossref"}]},{"name":"MSD","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006484","name":"AbbVie Deutschland","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100006484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014756","name":"Hexal AG","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100014756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010780","name":"Celltrion Healthcare","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,7,4]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The potential benefit of methotrexate (MTX) in combination with biologic (b) and targeted synthetic (ts) disease modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA) is still a matter of debate.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To compare clinical and patient reported characteristics as well as drug retention rates in PsA patients receiving b\/tsDMARD monotherapy or in combination with MTX.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>RABBIT-SpA is a prospective longitudinal cohort study including axSpA and PsA patients. In this analysis, PsA patients were stratified into two groups: starting b\/tsDMARD as monotherapy or in combination with MTX. Treatment retention was compared by drug survival analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>69% of the patients (n=900) started b\/tsDMARD as monotherapy while 31% were treated in combination with MTX (n=405). At baseline, clinical domains like skin, nail and joint affection, dactylitis, enthesitis and axial involvement were similar between the groups. Only the patients\u2019 satisfaction concerning tolerability of the previous treatment was significantly better in the combination group at treatment start. Drug retention rates did not differ between the groups (p=0.4). At 6\/12 months, 66%\/48% of patients in monotherapy and 67%\/48% in the combination group were still on their original treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We did not identify any clinical parameters with notable influence on the choice of b\/tsDMARD mono or MTX-combination therapy in PsA. Drug retention rates are similar between mono and combination therapy. It seems that the decision to continue MTX at initiation of b\/tsDMARDs is mostly based on the subjective tolerability of MTX treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2024-004389","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T22:36:05Z","timestamp":1721774165000},"page":"e004389","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["No difference in clinical parameters and drug retention in PsA patients receiving b\/tsDMARD monotherapy versus combination with methotrexate: data from the RABBIT-SpA registry"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2456-4049","authenticated-orcid":false,"given":"Anne Constanze","family":"Regierer","sequence":"first","affiliation":[{"name":"Epidemiology Unit, German Rheumatism Research Center Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kiefer","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet, Herne, Germany"},{"name":"Ruhr-Universit\u00e4t Bochum Medizinische Fakult\u00e4t, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany"},{"name":"Deutsches Zentrum Immuntherapie, Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Krause","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Clinical Immunology and Osteology, Immanuel Hospital Berlin-Wannsee Branch, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2069-2190","authenticated-orcid":false,"given":"Anja","family":"Wei\u00df","sequence":"additional","affiliation":[{"name":"Epidemiology Unit, German Rheumatism Research Center Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Sewerin","sequence":"additional","affiliation":[{"name":"Ruhr University Bochum, Bochum, Germany"},{"name":"Hiller Research Center, University Hospital of D\u00fcsseldorf, Dusseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6233-022X","authenticated-orcid":false,"given":"Anja","family":"Strangfeld","sequence":"additional","affiliation":[{"name":"Epidemiology Unit, German Rheumatism Research Center Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"2025090313593725000_10.3.e004389.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2025090313593725000_10.3.e004389.2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez383"},{"key":"2025090313593725000_10.3.e004389.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.07.001"},{"key":"2025090313593725000_10.3.e004389.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-022-01302-5"},{"key":"2025090313593725000_10.3.e004389.5","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-013-0316-4","article-title":"Psoriatic arthritis: phenotypic variance and nosology","volume":"15","author":"Eder","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"2025090313593725000_10.3.e004389.6","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000152"},{"key":"2025090313593725000_10.3.e004389.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"2025090313593725000_10.3.e004389.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"2025090313593725000_10.3.e004389.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225531"},{"key":"2025090313593725000_10.3.e004389.10","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24596"},{"key":"2025090313593725000_10.3.e004389.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-019-0613-z"},{"key":"2025090313593725000_10.3.e004389.12","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-021-02563-2","article-title":"Implementing an automated monitoring process in a digital, longitudinal observational cohort study","volume":"23","author":"Lindner","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2025090313593725000_10.3.e004389.13","doi-asserted-by":"crossref","unstructured":"Coyle C , Watson L , Whately-Smith C , et al . n.d. How do patient reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients. Rheumatol (Sunnyvale). doi:10.1093\/rheumatology\/kead679","DOI":"10.1093\/rheumatology\/kead679"},{"key":"2025090313593725000_10.3.e004389.14","doi-asserted-by":"publisher","DOI":"10.1159\/000528945"},{"key":"2025090313593725000_10.3.e004389.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.12.018"},{"key":"2025090313593725000_10.3.e004389.16","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00635-4"},{"key":"2025090313593725000_10.3.e004389.17","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141596"},{"key":"2025090313593725000_10.3.e004389.18","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000181","article-title":"Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the corrona registry","volume":"1","author":"Mease","year":"2015","journal-title":"RMD Open"},{"key":"2025090313593725000_10.3.e004389.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.40851"},{"key":"2025090313593725000_10.3.e004389.20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu415"},{"key":"2025090313593725000_10.3.e004389.21","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(22)00329-0"},{"key":"2025090313593725000_10.3.e004389.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221019"},{"key":"2025090313593725000_10.3.e004389.23","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00250-3"},{"key":"2025090313593725000_10.3.e004389.24","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2023-eular.1694","article-title":"POS1537\u2005Bimekizumab efficacy and safety in biologic dmard-na\u00efve patients with psoriatic arthritis was consistent with or without methotrexate: 52-week results from the phase 3 active\u2011reference study be optimal","volume":"82","author":"Mcinnes","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025090313593725000_10.3.e004389.25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab905"},{"key":"2025090313593725000_10.3.e004389.26","article-title":"Neither add-on nor withdrawal of methotrexate impacts efficacy of Il12\/23 inhibition in active PSA: data from a multicenter investigator-initiated randomized placebo-controlled clinical trial on arthritis, dactylitis, enthesitis, psoriasis, Qol and function","volume":"73","author":"Koehm","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025090313593725000_10.3.e004389.27","unstructured":"Poor SM , Henke M , Ulsh\u00f6fer T , et al . The role of antidrug antibodies in ustekinumab therapy and the impact of methotrexate. Rheumatol (Oxford) 2023."},{"key":"2025090313593725000_10.3.e004389.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.09.005"},{"key":"2025090313593725000_10.3.e004389.29","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091477"},{"key":"2025090313593725000_10.3.e004389.30","first-page":"672","article-title":"Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British society for rheumatology Biologics register","volume":"56","author":"Saad","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313593725000_10.3.e004389.31","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.064808"},{"key":"2025090313593725000_10.3.e004389.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.30117"},{"key":"2025090313593725000_10.3.e004389.33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220097"},{"key":"2025090313593725000_10.3.e004389.34","article-title":"Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis","volume":"4","author":"Fagerli","year":"2018","journal-title":"Data from the Br Soc Rheum Biologics Reg RMD Open"},{"key":"2025090313593725000_10.3.e004389.35","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2014.962081"},{"key":"2025090313593725000_10.3.e004389.36","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073544"},{"key":"2025090313593725000_10.3.e004389.37","doi-asserted-by":"publisher","DOI":"10.1002\/art.23333"},{"key":"2025090313593725000_10.3.e004389.38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202347"},{"key":"2025090313593725000_10.3.e004389.39","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14095","article-title":"Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis","volume":"54","author":"Exposito","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"2025090313593725000_10.3.e004389.40","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190815"},{"key":"2025090313593725000_10.3.e004389.41","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190299"},{"key":"2025090313593725000_10.3.e004389.42","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-017-0221-4"},{"key":"2025090313593725000_10.3.e004389.43","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223499"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-004389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:59:45Z","timestamp":1756933185000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-004389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,7,23]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1136\/rmdopen-2024-004389"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-004389","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}